Guardant Health Data Shows Higher Cancer Screening Adherence With Shield Test
Guardant Health, Inc. (GH) released new real-world and simulation data indicating that its Shield blood test significantly improves patient adherence to colorectal cancer screening compared to traditional stool-based options. In clinical modeling, Shield averted 12 deaths per 1,000 individuals, outperforming fecal immunochemical tests and multitarget stool DNA tests, which averted 6 and 9 deaths per 1,000 individuals, respectively.
The data also demonstrated strong real-world engagement, achieving 99% completion rates in two rural health clinics—substantially above the typical 28% to 71% historical adherence range in underserved regions. More than 200,000 Shield tests have now been completed. Higher adherence rates and increased follow-up colonoscopies could drive greater clinical adoption and recurring test volumes.
Investors and healthcare providers will be watching for potential expansions in health insurance coverage, inclusion in clinical practice guidelines, and concrete revenue figures to determine the long-term commercial impact of the test. Shares of Guardant Health were up 0.56% at 163 USD following the update.
Key points
- Guardant Health reported that its Shield blood test averted 12 colorectal cancer deaths per 1,000 people in simulations, compared to 6 and 9 for stool-based alternatives.
- Real-world testing in two rural clinics achieved a 99% screening adherence rate with Shield.
- More than 200,000 Shield tests have been administered to date.
- Higher adherence rates resulted in 679 colonoscopies per 1,000 patients with Shield versus 113 and 326 for stool tests.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
How effective is the Guardant Health Shield test compared to stool tests?
In computer simulations, Shield averted 12 colorectal cancer deaths per 1,000 people, compared to 6 deaths averted by FIT and 9 averted by mt-sDNA stool tests.
What is the adherence rate for Guardant Health Shield blood test?
Real-world data showed Shield achieved 99% adherence in two rural clinics, far higher than typical screening completion rates of 28% to 71%. Overall screening completion rates exceeded 90%.
How many Guardant Health Shield tests have been performed?
Guardant Health reported that over 200,000 Shield tests have been performed so far.